Business
Tempus Announces the Launch of Paige Predict
CHICAGO, January 21, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of Paige Predict, a suite of cutting-edge digital pathology applications that analyze hematoxylin and eosin (H&E) whole slide images to help inform testing decisions. The AI-powered solution is designed to predict the likely presence or absence of clinically actionable and relevant biomarkers directly from a single H&E slide, offering
About this update from Ai, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/84ecb84e6022801d640d909fbec7f4aa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dQqlt6mRYNRB.6.z2tyPzg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/84ecb84e6022801d640d909fbec7f4aa","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/eGQKlw4cX31G71NNdC8eQQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/84ecb84e6022801d640d909fbec7f4aa","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Following the acquisition of Paige in 2025, Tempus launches its new AI-powered, biomarker prediction solution for digital pathology","length":131,"tagName":"p","attribs":{}},{"type":"text","content":"CHICAGO, January 21, 2026--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of Paige Predict, a suite of cutting-edge digital pathology applications that analyze hematoxylin and eosin (H&E) whole slide images to help inform testing decisions. The AI-powered solution is designed to predict the likely presence or absence of clinically actionable and relevant biomarkers directly from a single H&E slide, offering physicians insights even when tissue samples are insufficient for full molecular profiling.","length":617,"tagName":"p"},{"type":"text","content":"As the demand for next-generation sequencing (NGS) and immunohistochemistry (IHC) testing grows, so does the challenge of limited tissue availability. When a sample is "quantity not sufficient" (QNS), patients can face delays of days or weeks for testing results, waiting for repeat biopsies or alternative testing, ultimately prolonging uncertainty and potentially impacting treatment options. Paige Predict’s ability to use an H&E image to identify biomarkers that are more or less likely to be present in the specimen can be used by clinicians to inform the sequence in which they will order confirmatory tissue-based tests, maximizing the likelihood of receiving an actionable result before exhausting tissue.","length":727,"tagName":"...